Head and Neck Carcinoma

A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC)

PMID 23406047 · Rosove et al., 2013 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.

PMID 16309541 · Thomas et al., 2005 · Open in CIViC

Study observed the effects of ribociclib (LEE011) on anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. qRT-PCR found Cyclin D1 mRNA to have significantly higher expression in A… (full text at CIViC)

PMID 29306020 · Lee et al., 2018 · Open in CIViC

Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). … (full text at CIViC)

PMID 27086918 · Chowdhury et al., 2016 · Open in CIViC

Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC)

PMID 28476872 · Skinner et al., 2017 · Open in CIViC

In 72 nonchemioradioselected (N-CRS) patients the CD44v9-positive by immunohistochemistry staining group demonstrated worse disease-specific survival than the CD44v9-negative groupe (p = 0.008) after … (full text at CIViC)

PMID 25751671 · Aso et al., 2015 · Open in CIViC

41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response … (full text at CIViC)

PMID 24239278 · Moreno-Galindo et al., 2014 · Open in CIViC

p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma.

PMID 24799460 · Argiris et al., 2014 · Open in CIViC

Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expre… (full text at CIViC)

PMID 25267748 · Chung et al., 2014 · Open in CIViC

Validating predominant overexpression of DDR2 in 554 head and neck squamous cell carcinoma (HNSCC) patients indicated the potentiality of utilizing dasatinib as a DDR2 inhibitor. From these patients, … (full text at CIViC)

PMID 27434411 · von Mässenhausen et al., 2016 · Open in CIViC

The primary tumor of A patient with head and neck squamous cell carcinoma with lung metastasis was not surgically resectable. Initial treatments led to stable disease and progression after 1 year. The… (full text at CIViC)

PMID 31011208 · Yang et al., 2019 · Open in CIViC

A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome ana… (full text at CIViC)

PMID 31871216 · Majounie et al., 2020 · Open in CIViC

3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC)

PMID 25677871 · Ansell et al., 2016 · Open in CIViC

The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC)

PMID 16943533 · Chung et al., 2006 · Open in CIViC

This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and dis… (full text at CIViC)

PMID 17538160 · Temam et al., 2007 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC)

PMID 23265711 · Licitra et al., 2013 · Open in CIViC

bp] In an in vitro study, a NIH3T3 cell line expressing EGFR P546S mutation demonstrated increased sensitivity to cetuximab treatment compared to NIH-3T3 cells expressing EGFR wild-type. Sensitivity w… (full text at CIViC)

PMID 23578570 · Bahassi et al., 2013 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

From a retrospective review of 38,095 tumor samples from 33,997 patients using DNA sequencing (MSK-IMPACT) and RNA sequencing (MSK-Fusion panel) identified 87 tumors with NTRK1-3 fusions. One case of … (full text at CIViC)

PMID 31375766 · Solomon et al., 2020 · Open in CIViC

Of 351 primary thyroid carcinoma patients assessed by targeted gene rearrangement next-generation assay, 11 cases (3.1%) had NTRK rearrangement. Only one case of EML4::NTRK3 fusion (e2,e13) with an in… (full text at CIViC)

PMID 32457407 · Chu et al., 2020 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

Case report of a 60-year old patient with p16 positive tumor of the tonsil with lung metastases after primary radiochemotherapy. The metastases were analyzed using a commercial molecular analysis and … (full text at CIViC)

PMID 28061634 · Seim et al., 2017 · Open in CIViC

In an in vitro study, a head and neck squamous cell carcinoma cell line OSC-19 expressing ERBB2 (HER2) S1050L mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib treatment… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In an in vitro study, an head and neck squamous cell carcinoma (HNSCC) cell line KYSE270 expressing ERBB3 (HER3) R1202W mutation was associated with insensitivity to cetuximab and erlotinib treatments… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

This retrospective preclinical study assessed the efficacy of afatinib towards head-and-neck squamous cell carcinoma (HNSCC) human cell lines expressing ERBB4 (HER4) G1109C mutation. According to the … (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In an in vitro study, a head and neck squamous cell carcinoma cell line SAS expressing ERBB4 (HER4) G1109C was associated with insensitivity to erlotinib treatment (IC50=1.47uM). Resistance was determ… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

A 53 year old female patient had PTC treated with surgery and multiple brain metastases. TERT c.-124C.T mutation and ETV6::NTRK2 fusion was found in pleural biopsy and cerebellar resection specimens.… (full text at CIViC)

PMID 35171659 · Park et al., 2022 · Open in CIViC

Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) h… (full text at CIViC)

PMID 26784937 · Prasad et al., 2016 · Open in CIViC

Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF an… (full text at CIViC)

PMID 16454808 · Hase et al., 2006 · Open in CIViC

This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. The authors conclude that evidence was found for prognostic value of FGFR1 expression in cancer-associated fibro… (full text at CIViC)

PMID 26115874 · Ipenburg et al., 2016 · Open in CIViC

FGFR2 p.P253R mutation detected in patient with head and neck SCC. Mutation initially detected by RNA-Seq and confirmed by Sanger sequencing. Patient is 52 y/o male with initial diagnosis of SCC of … (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with high-grade adenoid cystic carcinoma of the submandibular gland harboring an FGFR2 S252W (p.Ser252Trp) mutation achieved a partial response to … (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC)

PMID 26207647 · Jiang et al., 2015 · Open in CIViC

A 79 year old patient with prior 5-year history of Graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested … (full text at CIViC)

PMID 26788326 · Lu et al., 2016 · Open in CIViC

In this preclinical study, cell lines with constitutively-active G12V mutant found that forced overexpression of HRAS G12V caused a reduced susceptibility to PI3K inhibitor BYL719 in comparison to wil… (full text at CIViC)

PMID 30115483 · Ruicci et al., 2018 · Open in CIViC

In an in vitro study, a C643 cell line expressing HRAS G13R demonstrated reduced sensitivity to vemurafenib treatment, compared to BRAF V600E expressing cells (8505C, SWI1736, BHT101 and BCPAP). Sensi… (full text at CIViC)

PMID 19880792 · Salerno et al., 2010 · Open in CIViC

In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of… (full text at CIViC)

PMID 33750196 · Ho et al., 2021 · Open in CIViC

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC)

PMID 28954282 · Andersson et al., 2017 · Open in CIViC

Case report of a 62-year old male patient diagnosed with pancreatic acinar cell carcinoma. Liver metastases were diagnosed and treatment was started with gemcitabine plus nab-paclitaxel regimen. After… (full text at CIViC)

PMID 35005993 · Gaule et al., 2022 · Open in CIViC